Traws Pharma, Inc. (NASDAQ:TRAW) Stock Now Rated “Reduce” by Wall Street Analysts

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have earned a consensus rating of “Reduce” from the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $1.00.

TRAW has been the topic of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research note on Wednesday, August 26th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Traws Pharma in a report on Tuesday, August 18th. Citigroup lowered Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th.

Traws Pharma Stock Performance

Shares of NASDAQ:TRAW opened at $0.56 on Wednesday. The stock has a market capitalization of $8.66 million, a price-to-earnings ratio of -0.32 and a beta of 1.60. Traws Pharma has a 1-year low of $0.43 and a 1-year high of $3.27. The company’s fifty day moving average is $0.54 and its two-hundred day moving average is $1.09.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. Sell-side analysts expect that Traws Pharma will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Traws Pharma

An institutional investor recently bought a new position in Traws Pharma stock. Seven Fleet Capital Management LP purchased a new stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 49,260 shares of the company’s stock, valued at approximately $56,000. Seven Fleet Capital Management LP owned 0.62% of Traws Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 7.95% of the stock is owned by institutional investors.

About Traws Pharma

Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products.

Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections.